Program Description:
Fibrosing interstitial lung diseases (F-ILD) are a heterogeneous and progressive group of pulmonary disorders characterized by irreversible fibrosis, worsening lung function, and a substantial clinical and economic burden. F-ILD are driven by shared yet variable mechanisms that lead to relentless disease progression, acute exacerbations, and significant comorbidities. Patients with F-ILD experience high morbidity and mortality, impaired quality of life, and frequent health care resource utilization, including hospitalizations, emergency department visits, and long-term oxygen therapy. Despite advances in disease-modifying treatments such as antifibrotics, unmet needs remain, particularly in early diagnosis, treatment optimization, and slowing progression across diverse ILD subtypes. Late-stage and emerging therapies, along with advances in biomarker development, signal a rapidly evolving treatment landscape. However, delayed diagnosis, undertreatment, and barriers to access including complex prior authorization processes, high out-of-pocket costs, and the need for multidisciplinary care contribute to poor clinical outcomes and escalating direct and indirect costs. Managed care strategies, including value-based frameworks, real-world evidence integration, specialty pharmacy support, and formulary management, play a critical role in improving access and aligning treatment with current evidence. This webinar will provide pharmacists and managed care professionals with the latest clinical data, guideline updates, and practical strategies to address these challenges, optimize treatment selection, and improve outcomes for patients with F-ILD.
Target audience: Managed Care Pharmacists
Type of activity: Application
Release date: September
8, 2026
Expiration date: November 8, 2026
Time
to complete activity: 1 hour
Learner level: Foundational,
Intermediate
Fee: Free
Educational Objectives
At the completion of this activity, participants will be able to:
- Explore the pathophysiology and clinical burden of fibrosing interstitial lung diseases (F-ILD), differentiating idiopathic pulmonary fibrosis and progressive pulmonary fibrosis
- Evaluate recent clinical data on approved and emerging antifibrotic pharmacologic therapies for F-ILD to inform clinical decision-making and treatment selection.
- Apply current best practices and evolving treatment guidelines into evidence-based management strategies for patients with F-ILD.
- Assess the clinical, financial, and treatment burden of F-ILD and managed care strategies that facilitate timely access to appropriate interventions.
Rachael Prusi, PharmD, MSGH
Director, Specialty Clinical Solutions
Prime Therapeutics
Marquette, MI
Accreditation Information
Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.0 contact hour (0.10 CEU) under the ACPE universal activity number 0290-0000-26-239-L01-P. The activity is available for CE credit through November 8, 2026.
Obtaining Credit
All participants who attended the live virtual broadcast need to log on to their Pharmacy Times Continuing Education™ account on www.pharmacytimes.org to complete an online evaluation form and request their credit. Instructions on receiving credit will be provided the day of the event.
Disclosures
Rachael Prusi, PharmD, MSGH, has the following relevant financial relationship with an ineligible company to disclose: Employee of PBM: Prime Therapeutics
Pharmacy Times Continuing Education™ Planning Staff: Jim Palatine, RPh, MBA; Dipti Desai, PharmD, MBA, CHCP; Sarah Viruet; Brianna Winters; and Chloe Taccetta have no financial relationships with ineligible companies to disclose.
All of the relevant financial relationships listed for these individuals have been mitigated.
At least one anonymous peer reviewer has been used as part of content validation and conflict resolution. The peer reviewer has no relevant financial relationships with ineligible companies to disclose.
Educational Disclaimer
CPE activities are offered solely for educational purposes and do not
constitute any form of professional advice or referral. Discussions concerning
drugs, dosages, and procedures may reflect the clinical experience of the
author(s) or they may be derived from the professional literature or other
sources and may suggest uses that are investigational in nature and not
approved labeling or indications. Participants are encouraged to refer to primary
references or full prescribing information resources.
For questions about this internet CPE activity, please contact:
ceinfo@pharmacytimes.com
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms